Exact Sciences (NASDAQ:EXAS) Issues Earnings Results, Beats Estimates By $0.23 EPS

Exact Sciences (NASDAQ:EXAS) posted its quarterly earnings data on Wednesday. The medical research company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23, Zacks reports. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The firm had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Exact Sciences updated its FY 2025 guidance to EPS.

Exact Sciences Price Performance

NASDAQ:EXAS opened at $46.04 on Thursday. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. The stock’s 50 day moving average price is $55.41 and its two-hundred day moving average price is $60.10. The firm has a market capitalization of $8.52 billion, a price-to-earnings ratio of -40.81 and a beta of 1.24. Exact Sciences has a 12-month low of $40.62 and a 12-month high of $79.62.

Analyst Ratings Changes

A number of equities analysts recently commented on EXAS shares. BTIG Research raised their price objective on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. The Goldman Sachs Group decreased their target price on shares of Exact Sciences from $75.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. TD Cowen lifted their target price on shares of Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Citigroup decreased their target price on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Stifel Nicolaus decreased their target price on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, Exact Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $72.06.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.